Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5%

Short-Term Effect of Topical Brinzolamide 1%–Timolol 0.5% Fixed Combination on Human Central Corneal Thickness

“…The concentration of brinzolamide is 1% (10 mg/mL), equal to that of brinzolamide ophthalmic suspension (Azopt; Alcon Laboratories, Inc.) and the timolol concentration is 0.5% (5 mg/mL), equal to that of single-agent timolol. 12 Safety of FCBT has been demonstrated in several randomized studies. In 2 of the randomized controlled studies, the only systemic adverse event related to FCBT was dysgeusia, a distortion of taste, at an incidence of 3.2% in the ''Manni's non-inferiority study'' and 0.8% in the ''Mundorf's patient preference study.''…”

Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension

“…In a recent 6-month, double-masked, randomized, multicenter comparison of brinzolamide/timolol fixed combination in OAG and OHT, the IOP decrease varied between 18.9 and 20.8% with twice-daily brinzolamide 1%, and 22.8 and 26.1% with twice-daily timolol maleate 0.5% [14]. In the same investigation the corresponding figures found for the fixed combination varied between 29.6 and 33.5%, based on morning measurements.…”

A review on ocular findings in mouse lemurs: potential links to age and genetic background

“…Inflammatory processes, blood pressure and tumours can directly influence intraocular pressure (IOP) or damage involved structures and lead to drastic elevations of IOP (Kinshuck, 1991;Shields et al, 2001;Klein et al, 2005b;Radcliffe and Finger, 2009). Long exposure to increased IOP is one of the main risk factors for glaucoma development (Kass et al, 2002).…”

“…Constantly higher IOP needs medical intervention to prevent secondary disorders like glaucoma (Kass et al, 2002). In postoperative cases or cases of inflammatory processes like uveitis, treatment of increased IOP in humans and small animals can be the topical application of carbonic anhydrase inhibitors (Brinzolamide) and/or timolol (Kaback et al, 2008;Gelatt et al, 2012;Ornek et al, 2013;Takeuchi et al, 2017).…”

“…Inflammatory processes can be treated with a combination of antibiotics and topical steroid medication, whereas neoplastic causes usually need surgical treatment, as performed on small animals, for example (Gelatt et al, 2012). If increased IOP is involved, topical medication can be used, such as carbonic anhydrase inhibitors (Brinzolamide) and/or timolol (Kaback et al, 2008;Gelatt et al, 2012;Ornek et al, 2013;Takeuchi et al, 2017).…”